Astra Zeneca's COVID-19 vaccine
GPTKB entity
Statements (59)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:vaccine
|
| gptkbp:accessories |
gptkb:various_countries
|
| gptkbp:advocacy |
required before vaccination
|
| gptkbp:clinical_trial |
diverse population
Phase III conducted globally |
| gptkbp:community_health |
significant impact on pandemic control
|
| gptkbp:developed_by |
gptkb:Astra_Zeneca
|
| gptkbp:distribution |
global distribution
|
| gptkbp:dosage_form |
2 doses
recommended in some cases |
| gptkbp:emergency_services |
granted in multiple countries
|
| gptkbp:first_dose_interval |
4 to 12 weeks
|
| https://www.w3.org/2000/01/rdf-schema#label |
Astra Zeneca's COVID-19 vaccine
|
| gptkbp:is_effective_against |
approximately 76% effective
|
| gptkbp:is_vulnerable_to |
gptkb:Vaxzevria
logistical challenges intramuscular injection ongoing research for improvements funded by various organizations viral vector technology mixed public perception December 30, 2020 stable at refrigerator temperatures rapid development during pandemic effective against severe disease accelerated rollout in many countries addressed by health authorities adverse event monitoring system engagement with communities for education supply to low-income countries |
| gptkbp:manufacturing_process |
multiple facilities worldwide
|
| gptkbp:partnerships |
gptkb:Oxford_University
|
| gptkbp:regulatory_compliance |
various health authorities
|
| gptkbp:safety_measures |
ongoing safety monitoring
|
| gptkbp:side_effect |
fatigue
headache muscle pain nausea fever |
| gptkbp:storage |
2 to 8 degrees Celsius
|
| gptkbp:targets |
gptkb:COVID-19
|
| gptkbp:type |
viral vector vaccine
|
| gptkbp:vaccine_clinical_trial_results |
published in medical journals
|
| gptkbp:vaccine_communication |
public health campaigns
|
| gptkbp:vaccine_efficacy_against_severe_disease |
high efficacy against severe disease
|
| gptkbp:vaccine_efficacy_against_variants |
reduced efficacy against some variants
|
| gptkbp:vaccine_ethics |
ethical considerations in distribution
|
| gptkbp:vaccine_global_access |
aims for equitable access
|
| gptkbp:vaccine_impact_on_transmission |
may reduce transmission
|
| gptkbp:vaccine_long_term_effects |
studies ongoing for long-term effects
|
| gptkbp:vaccine_public_health_guidelines |
aligned with public health guidelines
|
| gptkbp:vaccine_public_health_strategy |
integrated into public health strategies
|
| gptkbp:vaccine_regulatory_challenges |
faced regulatory challenges in some regions
|
| gptkbp:vaccine_research_collaborations |
collaborations with global health organizations
|
| gptkbp:vaccine_research_updates |
regular updates on research findings
|
| gptkbp:whoapproval |
gptkb:World_Health_Organization
|
| gptkbp:bfsParent |
gptkb:Lonza_Group
|
| gptkbp:bfsLayer |
6
|